Article
Detection fidelity of AR mutations in plasma derived cell-free DNA.
Oncotarget - 28 Feb 2017
Goldstein Alexa, Toro Patricia Valda, Lee Justin, Silberstein John L, Nakazawa Mary, Waters Ian, Cravero Karen, Chu David, Cochran Rory L, Kim Minsoo, Shinn Daniel, Torquato Samantha, Hughes Robert M, Pallavajjala Aparna, Carducci Michael A, Paller Channing J, Denmeade Samuel R, Kressel Bruce, Trock Bruce J, Eisenberger Mario A, Antonarakis Emmanuel S, Park Ben H, Hurley Paula J
Abstract excerpt
Somatic genetic alterations including copy number and point mutations in the androgen receptor (AR) are associated with resistance to therapies targeting the androgen/AR axis in patients with metastatic castration resistant prostate cancer (mCRPC). Due to limitations associated with biopsying metastatic lesions, plasma derived cell-free DNA (cfDNA) is increasingly being used as substrate for genetic testing. AR...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.